FDA Panel Rejects Broad Olaparib Indication in Metastatic CRPC

[MEDPAGE TODAY]( Oncology Update Tuesday, May 02, 2023 [FDA Panel Rejects Broad Olaparib Indication in Metastatic CRPC]( ['Fantastic,' 'Terrific' Results With Oncolytic Virus Combo for Bladder Cancer]( [Enzalutamide-ADT Cuts Risk for Disease Spread in Nonmetastatic Prostate Cancer]( [Upfront Systemic Therapy, Deferred Surgery Pass Muster in Advanced Kidney Cancer]( [Novel Chemo Delivery System Achieves High Response Rate in Bladder Cancer]( ADVERTISEMENT Exclusives & Features [Feds Spent Even More on PrEP Combo Than Previously Thought]( [ACP Announces 'Ambitious' Effort to Improve Access to Obesity Care]( [Some Private Companies Charge Hefty Fees to Help Veterans With Disability Claims]( [Brain tumour survivor shaves head to raise awareness]( Clare Danswan says it took years before she learned a brain tumour was causing her epilepsy. [READ MORE]( [Uncoupling CD4+ TIL-mediated tumor killing from JAK-signaling in melanoma.]( INTRODUCTION: Impaired MHCI-presentation and insensitivity to immune effector molecules are common features of immune checkpoint blockade(ICB)-resistant tumors and can be respectively associated with... [READ MORE]( [Melanoma Monday: Tips to prevent the deadliest form of skin cancer]( Skin cancer is the most common type of cancer in the U.S. - and it's on the rise. On Melanoma Monday, experts share tips on how to protect yourself. [READ MORE]( [Asthma sufferers are 36 percent more likely to develop cancer]( But those who used steroids to treat their asthma appeared to have an elevated risk for fewer cancers than those who didn't treat their asthma with steroids. [READ MORE]( [Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial.]( PURPOSE: Patients with platinum resistant ovarian cancer (OvCa) respond poorly to existing therapies. Hence there is a need for more effective treatments.METHODS: The DeCidE1 trial is a multicenter,... [READ MORE]( [A Property of Everyday Health group]( © 2023 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Spec_Oncology_Update?xid=nl_mpt_Oncology_update_2023-05-02&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011